Nexgel Inc (NXGL) FinancialsNXGLNexgel Inc

Nexgel Inc (NXGL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Nexgel, accounting for 73.4% of total sales, equivalent to $1.95M. Another important revenue stream is CGN JV. Understanding this composition is critical for investors evaluating how NXGL navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Nexgel Inc maintains a gross margin of 30.09%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -67.96%, while the net margin is -97.83%. These profitability ratios, combined with a Return on Equity (ROE) of -128.61%, provide a clear picture of how effectively NXGL converts its operational activities into shareholder value.

In the context of the broader market, NXGL competes directly with industry leaders such as LOOP and HTOO. With a market capitalization of $1.78M, it holds a significant position in the sector. When comparing efficiency, NXGL's gross margin of 30.09% stands against LOOP's -67.52% and HTOO's 12.36%. Such benchmarking helps identify whether Nexgel Inc is trading at a premium or discount relative to its financial performance.

Nexgel has reported consistent net income losses, with the latest quarter showing a net income of -$3.64 million and a gross margin of only 30.09%. The forward P/E ratio is 1.381, indicating that while the stock may be undervalued, the underlying financial health is concerning.